Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001

The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2008-01, Vol.13 (7), p.863-873
Main Authors: PARKER, Scott, SCHRIEWER, Jill, OBERLE, Christina, ROBERTSON, Alice, LANIER, Randall, PAINTER, George, BULLER, R. Mark
Format: Article
Language:English
Subjects:
Alanine Transaminase - blood
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Aspartate Aminotransferases - blood
Biological and medical sciences
Biomarkers - analysis
Cell Line
Cytosine - administration & dosage
Cytosine - analogs & derivatives
Cytosine - therapeutic use
Disease Models, Animal
Disease Progression
DNA, Viral - blood
Ectromelia virus
Ectromelia virus - pathogenicity
Ectromelia, Infectious - drug therapy
Ectromelia, Infectious - physiopathology
Ectromelia, Infectious - virology
Female
Humans
Interferon-gamma - blood
Medical sciences
Mice
Organophosphonates - administration & dosage
Organophosphonates - therapeutic use
Pharmacology. Drug treatments
Treatment Outcome
Variola
Weight Loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a characteristic rash. Effective biomarkers will be required to monitor disease progression, guide the choice of therapeutic intervention strategies and evaluate their efficacies. To address this we have evaluated several biomarkers of disease in a lethal mousepox model. The efficacy of a single dose of a hexadecyloxypropyl ester of cidofovir (CMX001) at 20, 25 and 30 mg/kg doses administered on days 4, 5, 6 and 7 post-infection was evaluated in A/Ncr mice intranasally infected with low doses of ectromelia virus (
ISSN:1359-6535
2040-2058
DOI:10.1177/135965350801300703